MedPath

The First United Arab Emirates National Representative Birth Cohort Study

Recruiting
Conditions
Child and Maternal Health
Registration Number
NCT04928898
Lead Sponsor
United Arab Emirates University
Brief Summary

In this study, a multidisciplinary team of researchers was established including credible researchers from the UAE, Australia and the United Kingdom to launch the First United Arab Emirates 3-year birth cohort study. The study aims to recruit 250 pregnant Emirati women within their first trimester, which is defined by the study as from 8 to 12 weeks pregnant, recruited from obstetric and gynaecology clinics in the UAE. Participants will be recruited via face to face interviews and will receive a total of 11 visits with 1 visit in each trimester of pregnancy and 8 visits after delivery. Maternal data collection includes, socio-demographic and lifestyle factors, dietary intake, anthropometric measurements, physical activity, maternal psychological state, and blood samples for biochemical analysis. Post-partum, visits will take place when the child is 0.5, 4, 6, 9, 12, 18, and 24 months old, with data collection including infant anthropometric measurements, young child feeding practices, dietary intake, supplement use and the eating environment at home, as well as all maternal data collection described above, apart from blood samples. Additional data collection for the child includes developmental assessments taking place at three timepoints, 1) within 2 weeks of birth, 2) at 10-14 months and 3) at 22 - 26 months of age. Developmental assessments for the infant include vision, health, neurological examination, neurodevelopmental and sleep assessments.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
250
Inclusion Criteria
  • Emirati Nationality
  • Within first trimester of pregnancy (between 8 -12 weeks of gestation)
  • Singleton pregnancy
  • Absence of major illness preconception (Diabetes mellitus, hypertension, kidney disease, cancer, epilepsy, severe psychiatric illness, and other chronic diseases of infections such as autoimmune disorders, human immunodeficiency virus, and hepatitis).
Exclusion Criteria
  • Non-Emirati
  • Unconfirmed viable, intrauterine pregnancy at first obstetric ultrasound during first trimester
  • Twin or multiple gestation pregnancy and a history of multiple gestations
  • History of chronic illness (i.e., T2DM, hypertension, etc.)
  • Previously given birth to babies with malformation, intellectual disability, or inborn errors of metabolism.
  • Experience of a miscarriage before 28 weeks of gestation
  • On significant regular medications, including insulin, anti-hypertensive agents, psychotropic medications, anti-epileptic drugs, steroids, immune-suppressive agents, and chemotherapeutic agents.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Child anthropometric assessment (MUAC)24 months post-natal

Weight (kgs), length, head circumference, mid-upper arm circumference

Maternal Weight24 months post natal

Measured in Kilograms

Maternal Dietary Intake18 months post natal

Food frequency questionnaire

Maternal Blood Pressure3rd Trimester One point during weeks 27 - 42

Measured sphygmomanometer, in millimetres of mercury.

Maternal Physical Activity24 months post natal

International Physical Activity Questionnaire

Child neurodevelopmental assessment0.5 months post-natal

Neonatal Neurodevelopmental Assessment tool

Secondary Outcome Measures
NameTimeMethod
Maternal hemoglobin3rd Trimester One point during weeks 27 - 42

Hemoglobin levels measured in grams per deciliter

Maternal Ferritin3rd Trimester One point during weeks 27 - 42

Serum ferritin measured in nanograms per milliliter

Maternal Vitamin A3rd Trimester One point during weeks 27 - 42

Serum retinol measured in micrograms of retinol activity equivalent

Maternal lead concentration3rd Trimester One point during weeks 27 - 42

Serum lead measured in micromole per litre

Maternal Folate3rd Trimester One point during weeks 27 - 42

Serum folate measured in nanograms per milliliter

Maternal Vitamin B123rd Trimester One point during weeks 27 - 42

Serum B12 measured in picogram per millilitre

Maternal zinc concentration3rd Trimester One point during weeks 27 - 42

Serum zinc measured in micromole per litre

Maternal Vitamin D3rd Trimester One point during weeks 27 - 42

Serum 25 hydroxyvitamin D measured in nanomole per liter

Trial Locations

Locations (1)

United Arab Emirates University

🇦🇪

Al Ain, Abu Dhabi, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath